The TALORx trial evaluating the potential benefit of chemo-endocrine versus endocrine therapy alone in patients with hormone-receptor-positive human epidermal growth factor 2 receptor (HER2)-negative cancer and intermediate OncotypeDX, recurrence scores showed mostly equivocal results [14]. This evidence concerns the gene ERBB2 and cancer.